February 12, 2020 / 1:19 PM / 5 days ago

BRIEF-X4 Pharmaceuticals Granted New Composition Of Matter Patent For Late-Stage Clinical Candidate Mavorixafor

Feb 12 (Reuters) - X4 Pharmaceuticals Inc:

* X4 PHARMACEUTICALS GRANTED NEW COMPOSITION OF MATTER PATENT FOR LATE-STAGE CLINICAL CANDIDATE MAVORIXAFOR

* X4 PHARMACEUTICALS INC - PATENT EXPECTED TO PROVIDE EXCLUSIVITY THROUGH 2038 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below